Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin

Type 2 Diabetes Clinical Trial

Official title:

Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00753896
• Other study ID #: H8O-MC-GWDC
• Status: Completed
• Phase: Phase 3
• First received: September 15, 2008
• Last updated: April 20, 2015
• Start date: October 2008
• Est. completion date: November 2009

Study information

• Verified date: March 2015
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study will examine the safety of exenatide once weekly (2.0 mg) in approximately 134 patients receiving treatment with thiazolidinedione alone or thiazolidinedione in combination with metformin. Patients are expected to be treated with exenatide once weekly for at least 52 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 134
• Est. completion date: November 2009
• Est. primary completion date: July 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Have type 2 diabetes

• At least 18 years of age at screening.

• Have HbA1c of 7.1% to 10.0%, inclusive, at screening.

• Have a body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive.

• Have been treated with a stable dose of TZD (=4 mg/day rosiglitazone or =30 mg/day pioglitazone) for at least 120 days prior to Visit 1 OR Have been treated with a stable dose of TZD (=4 mg/day rosiglitazone or =30 mg/day pioglitazone) for at least 120 days PLUS a stable dose of metformin for at least 90 days prior to Visit 1.

• Have a history of stable body weight (not varying by >10% for at least 3 months prior to screening).

• If female of child-bearing potential (not surgically sterilized and between menarche and 1-year postmenopause) only.

• Are not breastfeeding.

• Test negative for pregnancy at the time of screening based on a serum pregnancy test.

• Intend not to become pregnant during the study.

• Have practiced a reliable method of birth control (e.g., use of oral contraceptives or approved hormonal implant; diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam; intrauterine devices; partner with vasectomy; or abstinence) for at least 6 weeks prior to screening.

• Agree to continue to use a reliable method of birth control (see above) during the study.

Exclusion Criteria:

• Have had a clinically significant history of cardiac disease or presence of active cardiac disease within the year prior to inclusion in the study, including myocardial infarction, clinically significant arrhythmia, unstable angina, coronary artery bypass surgery, angioplasty.

• Is expected to require coronary artery bypass surgery or angioplasty during the course of the study.

• Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis

• Have a history of renal transplantation or are currently receiving renal dialysis or have serum creatinine =135 µmol/L for males and =110 µmol/L for females.

• Have active or untreated malignancy, or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years.

• Have known hemoglobinopathy or chronic anemia (hemoglobin concentration <11.5 g/dL [115 g/L] for males, <10.5 g/dL [105 g/L] for females).

• Have clinically significant history or presence of severe gastrointestinal disease, particularly those which may impact gastric emptying, such as gastroparesis, pyloric stenosis, or gastric bypass surgery.

• Have a history of pancreatitis.

• Have had greater than three episodes of major hypoglycemia within 6 months prior to screening.

• Have any contraindication for the OAD(s) which they use, according to local label requirements.

• Are known to have active proliferative retinopathy.

• Are receiving chronic (>2 weeks) systemic glucocorticoid therapy (excluding topical or inhaled preparations) or have received systemic glucocorticoid therapy for >2 weeks within the 4 weeks immediately preceding screening.

• Have been treated with drugs that promote weight loss (e.g., Xenical® [orlistat], Meridia® [sibutramine], Acomplia® [rimonabant], Acutrim® [phenylpropanolamine], or similar over-the-counter medications) within 3 months of screening.

• Have previously been treated with glucagon-like peptide 1 analogs or liraglutide.

• Have been treated for longer than 2 weeks with any of the following excluded medications within 3 months prior to screening: Insulin; Sulfonylureas; Alpha-glucosidase inhibitors (e.g., Glyset® [miglitol] or Precose® [acarbose]); Meglitinides (e.g., Prandin® [repaglinide] or Starlix® [nateglinide]); Dipeptidyl peptidase (DPP)-4 inhibitors (e.g., Januvia™ [sitagliptin], Galvus® [vildagliptin]); Symlin® (pramlintide acetate).

• Have had an organ transplant.

• Have donated blood within 30 days of screening.

• Have previously completed or withdrawn from this study or any other study investigating exenatide once weekly.

• Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.

• Are currently participating in an interventional medical, surgical, or pharmaceutical study (a study in which an experimental, drug, medical, or surgical treatment is given). Patients completing the final visit of a study examining safety/efficacy of exenatide BID may enter this study on the same day if they meet other eligibility criteria.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type 2 Diabetes

Intervention

Drug:
• exenatide
subcutaneous injection, 2.0mcg, once weekly

Locations

Country	Name	City	State
Canada	Research Site	Ajax	Ontario
Canada	Research Site	Cambridge	Ontario
Canada	Research Site	New Westminister	British Columbia
Canada	Research Site	Windsor	Ontario
Mexico	Research Site	Chihuahua	Chiuahua
Mexico	Research Site	Distrito Federal
Mexico	Research Site	Monterrey	Nuevo Leon
Romania	Research Site	Baia Mare
Romania	Research Site	Brasov
Romania	Research Site	Bucharesti
Romania	Research Site	Craiova
Romania	Research Site	Iasi
Romania	Research Site	Suceava
South Africa	Research Site	Johannesburg
South Africa	Research Site	Pretoria
United States	Research Site	Atlanta	Georgia
United States	Research Site	Bowling Green	Kentucky
United States	Research Site	Chattanooga	Tennessee
United States	Research Site	Concord	California
United States	Research Site	Corvallis	Oregon
United States	Research Site	Fresno	California
United States	Research Site	Idaho Falls	Idaho
United States	Research Site	La Mesa	California
United States	Research Site	Memphis	Tennessee
United States	Research Site	Mesa	Arizona
United States	Research Site	Tempe	Arizona

Sponsors (2)

Lead Sponsor	Collaborator
AstraZeneca	Eli Lilly and Company

Countries where clinical trial is conducted

United States,  Canada,  Mexico,  Romania,  South Africa, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Patients Experiencing Adverse Events	Percentage of patients experiencing treatment-emergent adverse events over 52 weeks	Baseline to Week 52	Yes
Primary	Assessment of Event Rate of Treatment-Emergent Hypoglycemic Events	Major hypoglycemia: any episode with symptoms consistent with hypoglycemia that resulted in loss of consciousness or seizure with prompt recovery in response to administration of glucagon or glucose OR documented hypoglycemia (blood glucose <3.0 mmol/L [54 mg/dL]) and required the assistance of another person. Minor hypoglycemia: any sign or symptom associated with hypoglycemia that is either self-treated by the patient or resolves on its own AND has a concurrent finger stick blood glucose <3.0 mmol/L (54 mg/dL) and not classified as major hypoglycemia. Mean event rate = total number of events for all subjects in a treatment regimen / the total number of subject years of exposure for all subjects in that treatment. Standard error = square root of (total number of events / (subject years of exposure)**2).	Baseline to Week 52	Yes
Secondary	Change in HbA1c From Baseline to Week 52	Change in HbA1c from baseline to endpoint	Baseline, Week 52	No
Secondary	Percentage of Patients Achieving HbA1c <=7% at Week 52	Percentage of patients achieving HbA1c <=7% at endpoint (for patients with HbA1c >7% at baseline)	Baseline, Week 52	No
Secondary	Percentage of Patients Achieving HbA1c <=6.5% at Week 52	Percentage of patients achieving HbA1c <=6.5% at endpoint (for patients with HbA1c >6.5% at baseline)	Baseline, Week 52	No
Secondary	Change in Fasting Serum Glucose From Baseline to Week 52	Change in fasting serum glucose from baseline to endpoint	Baseline, Week 52	No
Secondary	Change in Body Weight From Baseline to Week 52	Change in body weight from baseline to endpoint	Baseline, Week 52	No
Secondary	Change in Total Cholesterol From Baseline to Week 52	Change in Total Cholesterol from baseline to endpoint	Baseline, Week 52	No
Secondary	Change in High-density Lipoprotein (HDL) From Baseline to Week 52	Change in HDL from baseline to endpoint	Baseline, Week 52	No
Secondary	Change in Triglycerides From Baseline to Week 52	Change in Triglycerides from baseline to endpoint	Baseline, Week 52	No
Secondary	Change in Blood Pressure From Baseline to Week 52	Change in Systolic and Diastolic Blood Pressure from baseline to endpoint	Baseline, Week 52	No